Axitinib medical insurance price in 2024

Axitinib (Axitinib) is an anti-tumor drug that is mainly used clinically to treat adult patients with advanced renal cell carcinoma (RCC) who have failed previous treatment with a tyrosine kinase inhibitor or cytokine. Axitinib is a second-generation oral VEGFR-1, 2, and 3 selective inhibitor that blocks VEGFR receptors at nanomolar drug concentrations, has a short half-life, and achieves minimal inhibition of other target proteins. Inhibits tumor growth by reducing the proliferation and differentiation of tumor cells.

In a phase III randomized trial (AXIS) that included723 patients, axitinib significantly prolonged the progression-free survival of patients compared with sorafenib. Common adverse reactions of this drug include diarrhea, high blood pressure, fatigue, etc.

Axitinib must be taken under the guidance of a doctor. The recommended dose is 5 mg twice a day, which can be adjusted according to the patient's safety and tolerance. During the treatment process, it may be necessary to alleviate some adverse drug reactions, such as reducing the dosage, suspending or terminating the medication, which should be done under the guidance of a doctor.

Overall, axitinib, as an effective anti-tumor drug, plays an important role in the treatment of renal cell carcinoma. Patients must strictly abide by medical instructions when taking the medicine to ensure the effectiveness and safety of the medicine.

Axitinib is currently sold in the domestic market and is also covered by medical insurance. Each box of the domestically marketed original drug contains 28 tablets of 5mg, and the market price is about 6,000 yuan. After medical insurance reimbursement, the price will be significantly reduced to about 2,000 yuan. However, please note that the reimbursement ratio of medical insurance will vary according to different regions. You can consult the local medical insurance department for specific ratios. The price of axitinib with the same specifications in foreign markets is about 6,000 yuan. In addition, Bangladesh Bikang Pharmaceutical has also launched a generic version of axitinib in overseas markets, with a specification of 5 mg and 60 tablets, priced at only 1,800 yuan.